Circulating Adipocytokines in Obese Nondiabetic Patients in Relationship with Cardiovascular Risk Factors, Anthropometry and Resting-Energy Expenditurede Luis D.A. · Gonzalez Sagrado M. · Conde R. · Aller R. · Izaola O. · Romero E.
Institute of Endocrinology and Nutrition, Medical School and Research Support Unit, Hospital Río Hortega, University of Valladolid, Valladolid, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Obesity and insulin resistance are associated with cardiovascular risk factors, including altered levels of inflammatory markers and adipocytokines. The aim of the present study was to examine the relationship between circulating adipocytokines and cardiovascular risk factors. Subjects: A population of 95 obese, nondiabetic outpatients was analyzed prospectively. A complete nutritional evaluation was performed. Results: In the multivariate analysis, with leptin as a dependent variable, only fat mass remained in the model (F = 66.6; p < 0.05), with an increase of 2.24 (95% CI 1.68–2.8) ng/ml of leptin with each 1 kg of fat mass. In a new model, with adiponectin as a dependent variable, the HDL cholesterol levels remained in the model (F = 8.46; p < 0.05), with an increase of 5.38 (95% CI 1.7–9.1) ng/ml of adiponectin with each 1 mg/dl of HDL cholesterol. In a third model, with interleukin 6 (IL-6) as a dependent variable, the resistin and C-reactive protein (CRP) levels remained in the model (F = 16.8; p < 0.01), with an increase of 0.48 (95% CI 0.27–0.85) pg/ml of IL-6 with each 1 ng/ml of resistin and an increase of 0.12 (95% CI 0.029–0.214) pg/ml with each 1 mg/dl of CRP. Conclusion: Circulating adipocytokine concentrations are associated with different cardiovascular risk factors in nondiabetic obese patients.
© 2007 S. Karger AG, Basel
- Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911–919.
- Meier U, Gressner AM: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem 2004;50:1511–1525.
- Matsuda M, Shimomura I, Sata M: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487–37491.
- Kumada M, Kihara S, Sumitsuji S: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85–89.
- Shimomoura I, Hammer RE, Ikemoto S: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73–76.
- Steppan CM, Bailey ST, Bhat S: The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
- Matsuzawa Y: Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep 2005;7:58–62.
- Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–414.
Feurer ID, Mullen JL: Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1986;1:43–49.
Pichard C, Slosman D, Hirschel B, Kyle U: Bioimpedance analysis in AIDS patients: an improved method for nutritional follow-up. Clin Res 1993;41:53a.
Mataix J, Mañas M: Tablas de composición de alimentos españoles. Granada, Editorial Universidad de Granada, 1998.
- Speakman JR, Stubbs RJ, Mercer JG: Does body mass play a role in the regulation of food intake? Proc Nutr Soc 2002;61:473–487.
- Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW: Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003;27:875–888.
Blum WF, Juul A: Reference ranges of serum leptin; in Blum WF (ed): Leptin – The Voice of Adipose Tissue. Heidelberg, Johann-Ambrosilus-Verlag, 1997, pp 318–326.
- Abdella NA, Mojiminiyi OA, Moussa MA, Zaki M, Al Mohammedi H: Plasma leptin concentration in patients with type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med 2005;22:278–285.
- Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730–1736.
- Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan C: Increased serum resistin in adults with Prader-Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005;90:4335–4340.
- Salmennienmi U, Zacharova J, Ruotsalainen E, Vauhkonen I, Pihlajamaki J, Kainulainen S, Punnonen K, Laakso M: Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:4216–4223.
- Mantzoros CS, Manson JE, Meigs J, Hu FB: Circulating adiponectin levels are associated with better glycemic control, more favourable lipid profile and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542–4548.
- Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B: Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and TNF alpha. Effect of weight loss in obese patients. Eur J Endocrinol 2003;148:535–542.
- Shetty G, Economides P, Horton E, Mantzoros C, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450–2454.
- Tschop M, Smiley DL, Heiman ML: Ghrelin induced adiposity in rodents. Nature 2000;407:908–913.
- Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273–2282.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.